Toll-like receptor (TLR) 2 specific and antagonistic monoclonal antibody
TLR2 represents an “earliest possible” target for prevention and therapeutic
intervention in the pathogenesis of harmful immune reactions whose blockage abrogates entry of the initial inflammatory signal into first-line defense host cells.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Nerve cells of blind mice retain their visual function
Nerve cells in the retina were analysed at TU Wien (Vienna) using microelectrodes. They show astonishingly stable behavior – good news for retina implants. The retina is often referred to…
State-wide center for quantum science
Karlsruhe Institute of Technology joins IQST as a new partner. The mission of IQST is to further our understanding of nature and develop innovative technologies based on quantum science by…
Newly designed nanomaterial shows promise as antimicrobial agent
Rice scientists develop nanocrystals that kill bacteria under visible light. Newly developed halide perovskite nanocrystals (HPNCs) show potential as antimicrobial agents that are stable, effective and easy to produce. After…